PTO/SB/21 (08-00)

Please type a plus sign (+) inside this box -> +

Approved for use through 10/31/2002. OMB 0651-0031

February 14, 2003

February 14, 2003

Date

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE tuction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| PE | Under | Under the Paperwork Red | | |
|-------------|--------|-------------------------|--|--|
| FEB 2 1 201 | Column | TRANS | | |
| TENTA TRAVE | be u | sed for all corre | | |

SMITTAL DRM

Total Number of Pages in This Submission 6

spondence after initial filing)

| 09/847,046 | | 7 2\ |
|-----------------|---|--|
| April 30, 2001 | <i>\(\)</i> | <u> </u> |
| Hevezi, et al. | , Ch | (g) |
| 1642 | C) | رک |
| Davis, Minh Tam | $\mathcal{L}_{\mathcal{L}}$ | 5 5 |
| 018501-008210US | | En) |
| | April 30, 2001 Hevezi, et al. 1642 Davis, Minh Tam | April 30, 2001 Hevezi, et al. 1642 Davis, Minh Tam |

| | | | <u> </u> | 49 | | | |
|---|-------------------------------|--|--|---|--|--|--|
| ENCLOSURES (check all that apply) | | | | | | | |
| Fee Transmittal F | orm | Assignment Pap | | After Allowance Communication to Group | | | |
| Fee Attached | | Drawing(s) | | Appeal Communication to Board of Appeals and Interferences | | | |
| Amendment / Reply | | Licensing-related Papers | | Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) | | | |
| After Final | | Petition | | Proprietary Information | | | |
| Affidavits/declaration(s) | | Petition to Convert to a Provisional Application | | Status Letter | | | |
| Extension of Time Request | | Power of Attorney, Revocation Change of Correspondence Address | | Other Enclosure(s) (please identify below): | | | |
| Express Abandonment Request | | ☐ Terminal Disclaimer ☐ Request for Refund | | Response to Restriction (2pp); Return Postcard | | | |
| ☐ Information Disclosure Statement | | CD, Number of | CD(s) | | | | |
| Certified Copy of Priority Document(s) | | Remarks | The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430. | | | | |
| Response to Missing Parts/ Incomplete Application | | | I | | | | |
| Response to Missing Parts under 37 CFR 1.52 or 1.53 | | | | | | | |
| SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT | | | | | | | |
| Firm | | wnsend and Crew LLF | | | | | |
| and Individual name | Kevin Bastian Reg. No. 34,774 | | | | | | |
| Signature | Rh | Khito | | | | | |
| Date | February 14, 2003 | } | | | | | |
| CERTIFICATE OF MAILING | | | | | | | |

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time/you are required to complete this form should be send to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Box Amendment, Commissioner for Patents, Washington, D.C. 20231 on this date:

SF 1433011 v1

Signature

Typed or printed name



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Attorney Docket No.: 018501-008210US Client Ref. No.: PRCA 003-1 US

Box Non-Fee Amendment, Assistant Commissioner for Patents

Washington, D.C. 20231 On February 14, 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Hevezi, et al.

Application No.: 09/847,046

Filed: April 30, 2001

For: NOVEL METHODS OF DIAGNOSIS OF PROSTATE CANCER AND/OR BREAST CANCER, COMPOSITIONS, AND METHODS OF SCREENING FOR PROSTATE CANCER AND/OR BREAST CANCER **MODULATORS**

Examiner:

Davis, Minh Tam

Art Unit:

1642

RESPONSE TO RESTRICTION

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In response to the Office Action mailed January 14, 2003, Applicants elect with traverse to prosecute the claims of Group II directed to methods of diagnosing prostate cancer by determining the mRNA expression of a gene encoding PAA3. According to the MPEP, where claims can be examined together without undue burden, the Examiner must examine the claims on the merits even though they are directed to independent and distinct inventions. See, the MPEP at 803.01. In establishing that an "undue burden" would exist for co-examination of claims, the Examiner must show that examination of the claims would involve substantially different prior art searches, making the co-examination burdensome. To show undue burden resulting from searching

Hevezi, et al.

Application No.: 09/847,046

Page 2

difficulties, the Examiner must show that the restricted groups have a separate classification, acquired a separate status in the art, or that searching would require different fields of search (MPEP at § 808.02). Applicants respectfully submit that both inventions in the present application can readily be searched without undue burden.

In light of the above, Applicants respectfully request that the restriction be withdrawn. If a telephone conference would expedite prosecution of this application, the Examiner is invited to telephone the undersigned at (415) 576-0200.

Respectfully submitted,

Reg. No. 34,774

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, 8th Floor San Francisco, California 94111-3834

Tel: 415-576-0200 Fax: (415) 576-0300

KLB:klb SF 1432993 v1